This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Houssaye, S. Articles by Varon, E. Search for Related Content PubMed PubMed Citation Articles by Houssaye, S. Articles by Varon, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2712-2715, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2712-2715.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae

L.R.M.A., INSERM E0004 Université Paris VI, 75270 Paris cedex 06,¹ C.N.R. des Pneumocoques, Hôpital Européen Georges Pompidou, 75908 Paris cedex 15, France²

Received 15 January 2002/ Returned for modification 4 March 2002/ Accepted 9 May 2002

We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.

This article has been cited by other articles:

• Balsalobre, L., de la Campa, A. G. (2008). Fitness of Streptococcus pneumoniae Fluoroquinolone-Resistant Strains with Topoisomerase IV Recombinant Genes. Antimicrob. Agents Chemother. 52: 822-830 [Abstract] [Full Text]  
• Amyes, S. G. B., Walsh, F. M., Bradley, J. S. (2007). Best in class: a good principle for antibiotic usage to limit resistance development?. J Antimicrob Chemother 0: dkm059v1-2 [Abstract] [Full Text]  
• Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
• Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
• Ling, J. M., Chan, E. W., Lam, A. W., Cheng, A. F. (2003). Mutations in Topoisomerase Genes of Fluoroquinolone-Resistant Salmonellae in Hong Kong. Antimicrob. Agents Chemother. 47: 3567-3573 [Abstract] [Full Text]  
• Sifaoui, F., Lamour, V., Varon, E., Moras, D., Gutmann, L. (2003). ATP-Bound Conformation of Topoisomerase IV: a Possible Target for Quinolones in Streptococcus pneumoniae. J. Bacteriol. 185: 6137-6146 [Abstract] [Full Text]  
• Masselot, F., Boulos, A., Maurin, M., Rolain, J. M., Raoult, D. (2003). Molecular Evaluation of Antibiotic Susceptibility: Tropheryma whipplei Paradigm. Antimicrob. Agents Chemother. 47: 1658-1664 [Abstract] [Full Text]  
• Ince, D., Zhang, X., Hooper, D. C. (2003). Activity of and Resistance to Moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415 [Abstract] [Full Text]